Chanelle Pharma
Chanelle Pharma is Ireland’s largest indigenous pharmaceutical manufacturer of both medical and veterinary products. With over 35 years of research and development, the company develops, registers, manufactures, and out-licenses generic pharmaceuticals for human and animal health, serving customers in 96 countries worldwide. Headquartered in Loughrea, Co Galway, Ireland, it operates three manufacturing facilities, four research and development laboratories, and employs 550 people across Ireland, UK, Jordan, and India. The company is committed to innovation, quality, and sustainability, and has a strong focus on animal welfare and community support.
Industries
Nr. of Employees
large (251-1000)
Chanelle Pharma
Dublin Road, Loughrea, Co Galway, Ireland
Products
Generic veterinary pharmaceuticals
Portfolio of generic products for small and large animals across categories such as anthelmintics, antibiotics, NSAIDs and supplements, supplied to global markets.
Generic human pharmaceuticals
Range of generic human pharmaceutical products developed and manufactured for international distribution.
Generic veterinary pharmaceuticals
Portfolio of generic products for small and large animals across categories such as anthelmintics, antibiotics, NSAIDs and supplements, supplied to global markets.
Generic human pharmaceuticals
Range of generic human pharmaceutical products developed and manufactured for international distribution.
Services
R&D services including product synthesis, formulation development, stability studies and pipeline product development across multiple R&D sites.
Regulatory strategy, dossier compilation and submission, pharmacovigilance, variations, renewals and international registration support.
Commercial manufacturing and product packaging services for human and veterinary generics provided from multiple manufacturing facilities.
Advisory services on product development, regulatory strategy and quality remediation to help partners overcome regulatory and quality barriers.
R&D services including product synthesis, formulation development, stability studies and pipeline product development across multiple R&D sites.
Regulatory strategy, dossier compilation and submission, pharmacovigilance, variations, renewals and international registration support.
Commercial manufacturing and product packaging services for human and veterinary generics provided from multiple manufacturing facilities.
Advisory services on product development, regulatory strategy and quality remediation to help partners overcome regulatory and quality barriers.
Expertise Areas
- Generic pharmaceutical development
- Veterinary pharmaceuticals
- Formulation and process development
- R&D pipeline management
Key Technologies
- Formulation development
- Process validation
- Stability testing
- Bioequivalence study methodology
News & Updates
Last year, Chanelle went through major changes including acquisition by a private equity firm and installation of new senior leaders. The CEO Angelo Gatto discussed the company's future and growth opportunities.
Jacob Kurdziel was appointed as Head of Corporate Development to drive the strategic growth and transformation of Chanelle Pharma.
Pat McLoughlin was appointed as General Manager to oversee operations across manufacturing, engineering, supply chain, and quality control.
An article discussing the company's recent changes, leadership, and growth prospects.
Announcement of the new appointment to lead corporate development efforts.
Recognition as one of the best managed companies in the industry.
Last year, Chanelle went through major changes including acquisition by a private equity firm and installation of new senior leaders. The CEO Angelo Gatto discussed the company's future and growth opportunities.
Jacob Kurdziel was appointed as Head of Corporate Development to drive the strategic growth and transformation of Chanelle Pharma.
Pat McLoughlin was appointed as General Manager to oversee operations across manufacturing, engineering, supply chain, and quality control.
An article discussing the company's recent changes, leadership, and growth prospects.
Announcement of the new appointment to lead corporate development efforts.
Recognition as one of the best managed companies in the industry.